13D Filing: OrbiMed Advisors and Adaptimmune Therapeutics PLC – ADR (ADAP)

Page 2 of 11

Page 2 of 11 – SEC Filing

SCHEDULE 13D
CUSIP No.  00653A107
1
NAME OF REPORTING PERSONS
OrbiMed Advisors LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
30,607,860
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
30,607,860
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
30,607,860
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.44%*
14
TYPE OF REPORTING PERSON (See Instructions)
IA
_______________________
* This percentage is calculated based upon 562,142,638 of the Issuer’s ordinary shares outstanding (including any such ordinary shares represented by ADSs (defined below)), as set forth in the Issuer’s Quarterly Report on Form 10-K filed with the SEC (defined below) on March 15, 2018.

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)

Page 2 of 11